IRLAB Therapeutics AB (publ) (IRLAB-A) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.787x

Based on the latest financial reports, IRLAB Therapeutics AB (publ) (IRLAB-A) has a cash flow conversion efficiency ratio of -0.787x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-24.18 Million ≈ $-2.60 Million USD) by net assets (Skr30.72 Million ≈ $3.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IRLAB-A market cap for the company's overall valuation and market capitalisation.

IRLAB Therapeutics AB (publ) - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how IRLAB Therapeutics AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

IRLAB Therapeutics AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of IRLAB Therapeutics AB (publ) ranked by their cash flow conversion efficiency. Explore IRLAB-A operating cash flow to net income to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Hank Payments Corp V:HANK	0.083x
NYESA VALOS CO.EO 001 F:7NY0	N/A
Bambuser AB ST:BUSER	-0.182x
PCCS Group Bhd KLSE:6068	0.196x
Sejoong Co. Ltd KQ:039310	-0.005x
New York City REIT Inc NYSE:NYC	-0.046x
Klaria Pharma Holding AB ST:KLAR	0.004x
Vereinigte Filzfabriken AG MU:VFF	N/A

Annual Cash Flow Conversion Efficiency for IRLAB Therapeutics AB (publ) (2014–2025)

The table below shows the annual cash flow conversion efficiency of IRLAB Therapeutics AB (publ) from 2014 to 2025. View IRLAB Therapeutics AB (publ) (IRLAB-A) share price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr30.72 Million ≈ $3.31 Million	Skr-55.22 Million ≈ $-5.94 Million	-1.798x	+10.56%
2024-12-31	Skr32.63 Million ≈ $3.51 Million	Skr-65.59 Million ≈ $-7.06 Million	-2.010x	-41.14%
2023-12-31	Skr115.76 Million ≈ $12.46 Million	Skr-164.85 Million ≈ $-17.74 Million	-1.424x	-190.40%
2022-12-31	Skr290.83 Million ≈ $31.30 Million	Skr-142.61 Million ≈ $-15.35 Million	-0.490x	-252.28%
2021-12-31	Skr399.48 Million ≈ $42.99 Million	Skr128.64 Million ≈ $13.84 Million	0.322x	+225.57%
2020-12-31	Skr347.88 Million ≈ $37.44 Million	Skr-89.21 Million ≈ $-9.60 Million	-0.256x	+48.87%
2019-12-31	Skr181.83 Million ≈ $19.57 Million	Skr-91.20 Million ≈ $-9.81 Million	-0.502x	-50.55%
2018-12-31	Skr212.48 Million ≈ $22.87 Million	Skr-70.79 Million ≈ $-7.62 Million	-0.333x	+10.56%
2017-12-31	Skr155.00 Million ≈ $16.68 Million	Skr-57.74 Million ≈ $-6.21 Million	-0.373x	+5.19%
2016-12-31	Skr103.89 Million ≈ $11.18 Million	Skr-40.82 Million ≈ $-4.39 Million	-0.393x	-30.74%
2015-12-31	Skr92.03 Million ≈ $9.90 Million	Skr-27.66 Million ≈ $-2.98 Million	-0.301x	-141.45%
2014-12-31	Skr88.57 Million ≈ $9.53 Million	Skr-11.02 Million ≈ $-1.19 Million	-0.124x	--

About IRLAB Therapeutics AB (publ)

ST:IRLAB-A Sweden Biotechnology

Market Cap

$15.76 Million

Skr146.47 Million SEK

Market Cap Rank

#25934 Global

#530 in Sweden

Share Price

Skr1.73

Change (1 day)

-0.46%

52-Week Range

Skr1.20 - Skr3.04

All Time High

Skr104.95